vimarsana.com
Home
Live Updates
FDA Accepts Review of Drug Application of Roflumilast Foam for Seborrheic Dermatitis : vimarsana.com
FDA Accepts Review of Drug Application of Roflumilast Foam for Seborrheic Dermatitis
It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.
Related Keywords
Arcutis Biotherapeutic ,
Neal Bhatia ,
Arcutis Biotherapeutics ,
Clinical Dermatology At Therapeutics Research ,
Drug Administration ,
Prescription Drug User Free Act ,
Clinical Dermatology ,
Therapeutics Clinical Research ,
Applied Topically ,
Investigator Global Assessment ,
New Drug Application ,
Roflumilast Foam ,
Seborrheic Dermatitis ,
Individuals Aged ,
Data Indicates Roflumilast Foam Helpful ,
vimarsana.com © 2020. All Rights Reserved.